Invincity

Invincity is a Houston-based biotechnology company focused on developing next-generation cancer immunotherapies designed to overcome resistance to existing checkpoint inhibitors. Founded by Dr. Michael Curran, a prominent researcher from the MD Anderson Cancer Center, the company leverages insights into the tumor microenvironment to turn non-immunogenic "cold" tumors into "hot" tumors. Its lead program, INV-101, is a potent, systemic STING (Stimulator of Interferon Genes) agonist aimed at activating the innate immune system to drive robust anti-tumor responses. Invincity's platform focuses on identifying and targeting pathways that suppress immune infiltration and activity within solid tumors. The company is currently advancing its pipeline through pre-clinical development toward initial clinical trials.